Ontario Genomics Welcomes New Board Members

Ontario Genomics’ New Board Members

As we sharpen our focus on commercialization, we’re delighted to introduce you to four new members of Ontario Genomics’ Board of Directors to help us chart a new course and achieve our strategic goals.

Maureen Adamson, President of Fleming College and Interim President and CEO of Colleges Ontario, has more than 25 years of leadership experience in the post-secondary, health care, government and non-profit sectors.

Maureen has served as Ontario’s deputy minister of Tourism, Culture and Sport and deputy minister of the Status of Women. Other previous roles include president and CEO of the Michener Institute for Applied Health Sciences, CEO of Cystic Fibrosis Canada and vice-president of corporate services at Mohawk College.

Her volunteer work includes chairing the board of directors for Research Canada, serving as vice-chair and commissioner for the Toronto Transit Commission, and the inaugural chair of the Scarborough Health Network hospital in 2018 through Covid. She has been the inaugural chair of the Scarborough Health Research Institute since 2021.

Ian Ash is an entrepreneur and technology executive with over 25 years of experience scaling innovative technology companies.

As Co-Founder of Dig Insights, he helped build the company into a global organization and launched the high-growth SaaS platform, Upsiide, leading to a successful private equity exit.

Ian brings deep expertise in commercialization, strategic planning, and building the frameworks that turn innovative ideas into profitable enterprises. He is passionate about helping bridge the monetization gap for science and technology start-ups.

Pierre Meulien was most recently the Executive Director of the Innovative Medicines Initiative and oversaw its transition to the Innovative Health Initiative, a €2.4 billion cross-sector initiative in the health innovation ecosystem in Europe. He is now an independent consultant in biomedical R&I.

Previously, Dr Meulien was President and CEO of Genome Canada (2010-15) and was Chief Scientific Officer for Genome British Columbia. He has also served as founding CEO of the Dublin Molecular Medicine Centre and worked in the private sector with the French biotechnology company Transgene, and with Aventis Pasteur (now Sanofi Pasteur) as Director of Research at the Marcy l’Etoile (France) facility and then Senior Vice President for R&D at the Willowdale site (Ontario).

Greg Pope is Managing Partner of GDLP Advisors Inc., where he provides financial expertise and leadership to a variety of organizations in a number of different sectors.

With his deep financial background in multiple industries spanning four provinces, he provides clients with experienced financial leadership in areas such as raising capital, M&A, and bolstering the overall strength & effectiveness of the finance function within publicly traded and private organizations.

Greg has served in directorship roles in both corporate and charitable environments, bringing over 15 years of experience as Chief Financial Officer in the restaurant, retail, information technology and healthcare industries. Greg is currently a member of Memorial University’s Faculty of Business Advisory Board and has previously served on the boards of the National Arts Centre Foundation, CNIB, and certain corporate entities.

Dominique Tertigas is a PhD candidate at McMaster University in the Department of Biochemistry and Biomedical Sciences in the lab of Dr. Michael Surette. Dominique’s PhD project focuses on the gut microbiome in inflammatory bowel disease (IBD). Her work combines microbiology, genomics, and metagenomics to discover novel pathogens in IBD. Dominique has been awarded several scholarships, including the Canadian Graduate Scholarship (Master’s) and Ontario Graduate Scholarships, to support her research.

Dominique is a part of McMaster’s Michael G. DeGroote Institute for Infectious Disease Research and Farncombe Family Digestive Health Research Institute. As a trainee in these institutes, Dominique helps organize student-run conferences, plan trainee workshops, and mentor trainees in learning bioinformatics. Dominique has also applied her expertise in microbiome research to additional projects investigating the microbiome in the context of antibiotics, probiotic use, One Health, and more!

Dominique brings these experiences and training perspectives to Ontario Genomics’ Board as the student representative.

Ontario Genomics is also bidding farewell to a couple of retiring board members.

  • Alan Winter (Former BC Innovation Commissioner) joined in October 2017 and was the Chair of the Governance, HR, and Nominating Committee and shared his extensive genomics and genome foundations expertise with the organization.
  • Tom Corr (Former President and CEO, Ontario Centres of Excellence) brought his deep innovation expertise when he joined the Board in September 2018, and held several roles including Chair of the Finance & Audit Committee, former Vice Chair of the Board, member of the Private Sector Advisory Committee (PSAC).

Both Tom and Alan have made lasting contributions to the organization by playing a central role in launching the 2021 Strategic Plan, supporting the organization through leadership transitions, as well as helping guide Ontario Genomics through the COVID-19 pandemic, an era that also saw the inception of BioCreate, our best-in-class accelerator. We are thankful for their years of deep commitment to our board.

What if we could?

25 years in and decades more to go at Ontario Genomics!

This year’s annual report comes at a milestone time and the past year has been a remarkable one with exciting progress in our health, cleantech and food and agriculture projects.

As Ontario Genomics marks its 25th year, we celebrate our success in funding cutting-edge science projects that are producing homegrown solutions to some of humanity’s biggest challenges. In this 2024-25 annual report, you’ll see how we’re backing real winners in precision healthcare, biotech SMEs, food biomanufacturing, environmental testing and waste upcycling.

Looking into the future of the province’s workforce, we also ensure Ontario’s young people are informed and inspired about all the exciting opportunities biotechnology is creating, and how they can be a part of it. Now, more than ever, Ontario Genomics is focused on getting innovative research out of the lab and into the real world for everyone’s benefit.

This report features several inspiring examples of how our exceptional team nurtures ideas into reality. We hope you’re as motivated by it as we are! What if we could is more than a theme, it’s a commitment to transforming scientific discovery into practical, market-ready solutions. As Ontario Genomics enters its next 25 years, we will continue to turn this vision into impact for Ontario, Canada and the world.

Ontario Genomics’ Regional GAPP

Regional Genomic Applications Partnership Program (GAPP)

Fuelling Ontario’s Next Generation of Biotech Spinouts

Ontario Genomics is launching our Regional Genomic Applications Partnership Program (GAPP) to accelerate the commercialization of academic discoveries into made-in-Ontario biotech solutions.

Ontario is home to world-class researchers and institutions producing groundbreaking discoveries, yet many of them fail to progress beyond the lab. That’s because spinout companies (formed to commercialize academic intellectual property) that bring these innovations to market are often stifled by insufficient access to capital, long commercialization timelines and limited business expertise.

Thanks in part to a four year, $4 million commitment from Genome Canada, Ontario Genomics’ Regional GAPP is addressing these challenges by supporting spinouts at this critical lab-to-company technology transfer stage, facilitating R&D capacity, independence from academia and positioning them for seed financing. The end results will fuel job creation, company retention, IP generation and attract foreign investment, while reinforcing Ontario’s economic resilience and global reputation in genomics innovation.

Eligibility Criteria:

  • Your spinout company is incorporated in Canada and based in Ontario
  • Your spinout can commit $222,578 cash or in-kind over the two years of the program
  • Your technology is genomics or biotech enabled
  • Your spinout company is partnered with an Ontario-based researcher
  • Your company has at least two people (if the lead project researcher is also the CEO, the company’s governance board must have at least one additional member)

If you meet the above criteria, please visit the program page and fill out the intake form by Oct 24th.

The Canadian Biotechnology Innovation and Commercialization initiative (CBIC) is here!

Canadian Biotechnology Innovation and Commercialization (CBIC)

Ontario Genomics is playing a role

With the power of genomics, we now have a deeper understanding of the genetic basis of life, which is driving innovation across multiple sectors. This allows us to use biotechnology tools in medicine, agriculture and environmental science to solve global challenges and enhance our quality of life.

To boost commercialization, Genome Canada has made its first strategic investment to address Canada’s urgent health and industry challenges. Ontario Genomics is leading a key project that reduces the need for prostate biopsies by predicting the risks of high grade prostate cancer (HGPrCa) with biomarkers from semen.

Read more about Prostate Cancer Predict led by FlowLabs and Dr. Keith Jarvi, Sinai Health.

BioCreate Cohorts 6 & 7 are now open

BioCreate Program

Attention start-ups!
BioCreate applications are now open

Ontario Genomics’ BioCreate accelerator is now open to small- and medium-sized enterprises (SMEs) in southern Ontario looking to commercialize genomics and engineering biology enabled products and/or technologies in the health, food and agriculture and cleantech sectors at a Technology Readiness Level (TRL) of 4+.

What does BioCreate do? We provide funding, access to mentorship and unique business support to help companies bring new products and technologies to market.


Program Highlights:
  • Direct, non-repayable funding of $150,000.
  • Access to 18 months of intensive business mentorship and critical infrastructure through Ontario Genomics’ strategic sectoral and regional partnerships.
  • An investor showcase for each cohort, giving companies the opportunity to pitch to investors and potential partners.
Online Program Info Session

If you’re interested in learning more about BioCreate, join us Thursday, June 12 at noon for a 30 minute run down on program eligibility, application timelines and what to expect along your BioCreate journey. Whether you’re in health, agri-food or cleantech, this is your chance to bring your genomics-enabled innovation to market with world-class support backing you up.

Biocreate header with three phases
Application Steps and Dates
Interested? Review the Program Guide for more information on BioCreate, including eligibility requirements and evaluation criteria, then fill out the BioCreate intake form and a representative from our team will reach out to discuss your project idea. Eligible applicants will be invited to submit an application. If you have questions, please contact BioCreate@ontariogenomics.ca. The deadline to submit an intake form is July 31. Additional details and the application process can be found on the BioCreate page.

The BioCreate program is supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) and Ontario Genomics.

eDNA Surveillance can tell us nature’s secrets

As humans, we don’t live in a bubble. We’re connected to all living things around us, so it only makes sense to better understand the impact humans, animals and the environment have on each other. That’s where Environmental DNA (eDNA) comes in!

This advanced surveillance technique is emerging as a non-invasive and population-level method to better understand how our changing climate is impacting all living things, especially human health. Ontario Genomics is funding two new projects through Genome Canada’s eDNA Surveillance Initiative that gives regional support to better develop more sensitive and accurate detection methods.

One project will help two First Nations communities develop and implement new eDNA/eRNA tools for wastewater and ecological monitoring, while the other will track and correlate environmental and clinical antimicrobial resistance. An ethical and inclusive governance policy framework will be co-created with First Nations communities to ensure privacy protection, confidentiality and data integrity while respecting Indigenous sovereignty.

For more information, contact Laura Riley, Director, Sector Innovation & Programs.

eDNA-Surveillance-Initiative

Biomanufacturing and the Circular Bioeconomy

In our last post, we talked about how biomanufacturing thrives when circular economy principles are applied to emphasize sustainability throughout the entire lifecycle of bioproducts. This shift in mindset goes beyond adopting new practices—it’s a rethinking of production and consumption.

We’re all well-versed in this concept, whether we recognize it or not. Natural ‘economies’ are nearly always circular in nature – think about the carbon cycle, where carbon is released from dead plants and animals, reabsorbed by the soil and microbes within it, and then reincorporated into new organisms; or the water cycle, where constant cycles of evaporation and precipitation renew the planet’s water resources naturally. In fact, our current economy is the exception to the rule. By creating circular manufacturing processes and eliminating waste, we can restore our environment while maintaining strong economic growth.

Adopting a circular economy mindset in biomanufacturing goes beyond merely adopting new practices. It signifies a profound shift in the way we think about production and consumption. While it can be daring to challenge the status quo, several industries have recognized the importance of a circular economy as the viable path forward. This is made possible through three key values:

  1. Collaboration over competition: Industries, manufacturers, and consumers must collaborate throughout the lifecycle. It’s about sharing resources, knowledge, and best practices to create a sustainable ecosystem. The wasteCANcreate upcycling consortium is a great example of this in action!
  2. Long-Term Perspective: Prioritizing long-term environmental and social impacts over short-term profits ensures sustainability.
  3. Consumer Engagement: Empowering consumers to make informed choices supports businesses committed to circularity and responsible consumption habits.
Real-World Examples

Several companies are already putting these principles into action. Ontario Genomics’ industry partners, including IGPC Ethanol, EcoPoly Solutions, and lululemon athletica, all share these values and are working together to create more impact than any of them could individually.

IGPC Ethanol has transformed distillers’ grains—once considered waste—into a highly nutritious animal feed ingredient and are now looking for even better ways of upcycling these by-products, including in the production of packaging materials. This is just one way the circular economy can create value while reducing waste. As Sheena Alexander, Director of Strategy & Innovation at IGPC, explains:

At IGPC, we believe that circularization and upcycling are not just buzzwords but critical strategies for a sustainable future. Embracing the circular economy mindset in biomanufacturing isn’t just about changing processes; it’s a shift in perspective that drives innovation and sustainability across the entire product lifecycle“.

EcoPoly Solutions and lululemon athletica, are also collaborating to make an impact by testing materials produced through circular processes. By sharing resources and insights within the consortium, these companies demonstrate that the circular economy is not just a trend but a transformative force reshaping the way we produce and consume.

These companies are an example of what is possible. By adopting circular principles and embracing a sustainable mindset, we can reduce waste, conserve resources, and protect our biosphere for future generations. Our planet’s future depends on it.

The upcycling process

John M. Rafferty joins Ontario Genomics as new President & CEO

Ontario Genomics Names John M. Rafferty as New CEO to Champion Made-in-Ontario Innovation

Ontario Genomics is pleased to announce the appointment of John M. Rafferty as its new President & Chief Executive Officer, effective March 31, 2025. A visionary and dynamic leader with 25 years of experience driving innovation and impact in diverse organizations, John brings extensive experience in advancing transformative initiatives across sectors.

John joins Ontario Genomics following his tenure as President & CEO of CNIB, where he led the organization through a period of unprecedented growth and impact, expanding its national reach and strengthening partnerships across industries. His leadership in fostering innovation, strategic collaborations, and policy advocacy has been instrumental in creating meaningful change for blind individuals and communities across Canada.

As he steps into his new role at Ontario Genomics, John is committed to accelerating the commercialization of innovative genomic technologies and advancing “made-in-Ontario” solutions to address some of the world’s greatest challenges. Under his leadership, Ontario Genomics will continue to build strong partnerships between researchers, industry, and government to unlock the full economic and societal potential of genomics in Ontario and beyond.

We are also pleased to announce the promotion of Dr. Jordan Thomson to Chief Scientific Officer and Head of Commercialization. Jordan steps into his new role after successfully serving as COO for the past thirteen months. Jordan’s deep expertise in genomics technologies and their commercialization pathways, coupled with John’s leadership, will create a powerful team to drive market adoption and impact.

We also extend our deepest gratitude to Stephen Cummings, who has served as Interim President & CEO for the past year. His steadfast leadership has been instrumental in guiding Ontario Genomics through a pivotal period of transition. Stephen’s dedication has strengthened our position as a leader in the genomics ecosystem, and we thank him for his invaluable contributions.

Please join us in welcoming John to Ontario Genomics and watch this space for more exciting news in the weeks ahead!

The Future of Food is Coming but is Canada Ready?

New Report Projects an $18.8 Billion Food Biomanufacturing Industry for Canada

Following up on its 2021 report, Ontario Genomics has updated economic analysis for Canada’s food biomanufacturing sector in the Food Innovation in Canada Report, which shows explosive economic and job creation opportunities across the country. Cellular agriculture, or food biomanufacturing, is the process of using precision fermentation, cell cultivation or tissue engineering to make various foods, ingredients and even textiles that are usually made through traditional agriculture and manufacturing.

Along with input and feedback from researchers and organizations that specialize in food security and innovation, Dr. Michael von Massow at the University of Guelph, provided the economic analysis for this ground-breaking report on the future of precision fermented and cultivated foods in Canada. Here are some of the highlights:

  • Food biomanufacturing in Canada could become an $18.8 billion industry creating 125,000 jobs as soon as 2050, with greater growth in the long term.
  • Ontario could lead the country in food biomanufacturing with a $13 billion industry potential that could create over 91,000 jobs.
  • A cohesive national strategy, large-scale production facilities, research and commercial development support, and an agile regulatory process are needed to help Canada reach its potential and stay globally competitive.

Report author and Director of Strategic Partnerships, Elaine Corbett, says, “This report shows government and food producers the massive economic potential for food biomanufacturing in our country and gives the data needed for a national strategy and investment. This kind of food innovation is already happening around the world and considering the shifting economic climate, Canada needs to do even more to develop this manufacturing for Canadians but also to export to other countries.

Since the 2021 report, there has been significant growth in the number of Canadian companies, investment, research and development, but more support is needed to help this industry overcome commercial scale-up challenges.

Ontario Genomics is a non-profit organization funded by the Government of Ontario and other partners. Since 2000, we’ve been involved with cutting-edge science to find homegrown solutions to challenges the world faces like climate change, food insecurity and in healthcare.

Canada launches the most ambitious genomic health research program in Canada history: The Canadian Precision Health Initiative

The Canadian Precision Health Initiative (CPHI) is a $200M investment from the Government of Canada, through Genome Canada, to help transform Canada’s healthcare approach into a modern, precision health system.

Supported by the regional Genome Centres, including Ontario Genomics, this initiative will build Canada’s largest-ever collection of human genomic data —more than 100,000 genomes. This database will represent Canada’s diverse population to ensure precision health innovations benefit all.

Canadian Precision Health Initiative (CPHI)

CPHI partners will work together to build a coordinated precision health community that will:

  • Build a Canadian alliance for genomics in health to align efforts across Canada’s complex, federated health and research ecosystems.
  • Mobilize and advance the utility of genomic health data, working with academia and industry to ensure they have the right data assets and AI-powered tools to deliver life-saving solutions.
  • Implement data governance and policies ensuring the ethical and responsible use of genomic data.

Ontario Genomics is the lead for 4 awarded projects and the co-lead for 2 awarded projects. These projects will help generate high-quality genomic data that can be shared and securely used by researchers and clinicians across Canada. Learn more about these projects below:

Expanding the Use of Genomics to Unravel Rare Diseases: Care4Rare EXPAND

Project Leaders: Kym Boycott (University of Ottawa/Children’s Hospital of Eastern Ontario Research Institute), Christian Marshall (University of Toronto/Hospital for Sick Children), Francois Bernier (University of Calgary), Jacques Michaud (Université de Montréal/CHU Ste Justine)

Genome Centres: Ontario Genomics, Genome Alberta, Génome Québec

INFANT: Identifying At-risk Newborns from the Analysis of NGS Testing

Project Leaders: Kristin Kernohan, Neal Sondheimer, Melanie Lacaria, Erika Bariciak, Pranesh Chakraborty, Matthew Henderson (Children’s Hospital of Eastern Ontario Research Institute)

Genome Centre: Ontario Genomics

Precision Child Health – Comprehensive Sequencing for Childhood Life-long Disorders

Project Leaders: Stephen Scherer, Seema Mital, David Malkin, Linda Hiraki, Amanda Ricciuto, Gregory Costain, Yiming Wang, Ronald Cohn (Hospital for Sick Children)

Genome Centre: Ontario Genomics

Precision Health Network for Neurodevelopment, Mental Health and Brain Injury

Project Leaders: Evdokia Anagnostou (Holland Bloorview Research Institute), Jennifer Crosbie, Stephen Scherer, Louise Gallagher (The Hospital for Sick Children), Jacob Vorstman (Hospital for Sick Children), Darcy Fehlings (University of Toronto/Holland Bloorview Research Institute), Roger Zemek (Children’s Hospital of Eastern Ontario Research Institute), Danielle Andrade (University Health Network)

Genome Centre: Ontario Genomics

Genomic Evidence for Precision Medicine for Selected Chronic Diseases among Black Peoples in Canada

Project Leaders: Upton Allen (Hospital for Sick Children), Loydie Jerome-Majewska (McGill University), OmiSoore Dryden (Dalhousie University), Juliet Daniel (McMaster University)

Genome Centres: Genome Atlantic, Génome Québec, Ontario Genomics

Longitudinal, Deep-Phenotyped Pediatric Databank of Medical and Drug Therapy Outcomes

Project Leaders: Bruce Carleton (University of British Columbia), Michael Rieder (University of Western Ontario), Maja Krajinovic (Université de Montréal)

Genome Centres: Genome British Columbia, Genome Alberta, Génome Québec, Ontario Genomics